2 pm..eqip play, t/a sideways....recent PLYMOUTH, Minn., Dec. 9 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV - News), a global endovascular device company, announced today that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0.035" and NanoCross 0.014" peripheral angioplasty balloon catheters. ev3 expects to begin full commercialization of the EverCross and NanoCross peripheral balloon catheters globally in January 2009"..down 44% since the last JPM conf when I wrote..Not Sexy. Featured on the lighting round tonight. Jim Cramer indicated it was too difficult. Medical Instruments Catheter-based tech for vascular disease and stents. Missed their qtrs. no earnings.

2 pm...They were developing diabetis stuff which failed..they now have their zinc fingerprint which they just licence to companies for about 3M..been trending up...worth checking out...well this biotech is down 71% since the last jpm conf..ouch..jim was bearish..lol..I think he was right...this is what I saw..You know Jim C on 10/22 was Bearish..but this can be Sexy. Especially because we have 13d's by Koop Investment Advisors that bought 7.23% in Nov and 1-4-08 just got another 7.30%. In Dec the company issued a Press Release on Their Pipeline..and here it is..Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives Company Updates on Four Phase 2 Clinical Trials Dow AgroSciences CEO Discusses Future Opportunities with Sangamo Technology NEW YORK, Dec 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company will provide an update on milestones achieved in 2007 and preview objectives for 2008 during its annual Investor and Analyst Briefing held in New York City today. Jerome Peribere, President and CEO of Dow AgroSciences will discuss the success of the two companies' collaboration to develop zinc finger DNA-binding protein (ZFP) technology for use in plant agriculture and Dow AgroSciences' future plans to commercialize the technology. Mr. Peribere will be joined by Edward Lanphier, Sangamo's President and CEO and other members of Sangamo's senior management team. "We have been very pleased with the progress of our collaboration with Sangamo and by the success that we have had together to confirm our conviction that the ZFP platform has the ability to truly transform the field of plant genetics," commented Mr. Peribere. "We have established that Sangamo's ZFP technology can be used to regulate and modify genes in plants with great specificity and reliability. This enables significant savings in both the rate and cost of development of new crop products with improved traits, characteristics and regulatory designation. We envision that the application of ZFP-mediated gene modification and regulation will become a major component of our plant biotechnology process and, as we enter commercialization and sublicensing, will have a 'game-changing' role in the future of plant breeding." "The past year has been an exciting and transformational period for Sangamo in which we have successfully achieved several major goals," said Edward Lanphier, president and CEO of Sangamo. "The progress that we have made this year in both clinical and business development activities put us in a very strong position to continue to advance and commercialize our ZFP technology in therapeutics, plant agriculture, laboratory reagents and enhanced cell-lines for pharmaceutical protein manufacturing. We expect 2008 to be another year of significant accomplishments for Sangamo as we achieve a number of major value-creating events." Mr. Lanphier continued, "We presented positive top-line clinical data from our Phase 1b trial of our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) for the treatment of diabetic neuropathy (DN). Sangamo is building on this positive data by initiating further clinical trials as we continue our efforts to develop this technology as a novel platform for therapeutic development. This year we also achieved our goal of successfully completing the accrual of subjects to the Phase 2 trial of SB-509 for DN which will give us data in the second half of 2008. In addition to our two Phase 2 clinical trials in DN, we have announced our plans to initiate further Phase 2 studies of SB-509 in stem cell mobilization and amyotrophic lateral sclerosis (ALS) and to initiate two Phase 1 clinical trials in ZFP-mediated gene modification for glioblastoma and HIV/AIDS. We have also advanced and expanded our preclinical pipeline and presented data from several programs at major scientific and medical meetings. "We also continued to monetize our technology outside of the human therapeutic space. This year we established a major relationship with Sigma-Aldrich Corporation to develop and commercialize ZFP-based laboratory research reagents. We also entered into several cell-line engineering collaborations including a commercial license agreement with Genenetech. The research phase of our collaboration with Dow AgroSciences to apply our ZFP technology for plant agriculture applications is going very well as demonstrated by the achievement of multiple milestones and we look forward to moving into the commercial phase by the fourth quarter of 2008. "By the second half of 2008, we expect to have data from two Phase 2 trials in patients with diabetic neuropathy, to have initiated two new trials of SB-509 in stem cell mobilization and ALS, and two new Phase 1 trials in patients with HIV infection and glioblastoma. Achievement of these objectives, as well as commercial progress in our collaboration with Sigma and entry into the commercial phase of our collaboration with Dow AgroSciences, will be key to further enhancing the market-leading presence for our technology. As has become increasingly evident, an innovation gap exists in the pharmaceutical sector, and we believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential partners for our ZFP Therapeutic programs." Sangamo Accomplishments in 2007 During the briefing several of the company's achievements will be highlighted including: -- Sangamo presented "top-line" clinical data from its ZFP Therapeutic program to develop SB-509, a ZFP activator of VEGF for the treatment of diabetic neuropathy at both the Annual Scientific Sessions of the American Diabetes Association in June and the Society for Neuroscience Annual Meeting in November. The data showed statistically significant improvements in several measurements of neurologic health in subjects with mild to moderate diabetic neuropathy over a six-month period after treatment with a single administration of SB-509. -- Sangamo completed accrual for its repeat-dosing Phase 2 trial of SB-509 in patients with mild to moderate DN, and anticipates having data from this trial in the second half of 2008. -- Successful prosecution of Sangamo's collaboration with Dow AgroSciences has resulted in the achievement of several research milestones including the first demonstration of ZFN-mediated targeted integration of DNA into a native gene in maize and the first demonstration of targeting a native gene in canola with ZFNs. -- Sangamo established a major alliance with Sigma-Aldrich Corporation to develop and commercialize high value laboratory research reagents based upon Sangamo's zinc finger DNA binding protein technology. In July 2007, as part of the agreement, Sangamo received an upfront payment of $13.5 million which included license fees and the purchase of one million shares of Sangamo stock. Sangamo is also eligible to receive development and commercial milestone payments of up to $24 million, sublicense payments and royalties on product sales. -- Further strengthening its balance sheet, Sangamo completed a registered direct offering of its common stock. In July 2007, Sangamo sold an aggregate of 3,278,689 shares of common stock to a group of institutional investors in a registered direct offering, resulting in gross proceeds to the company of approximately $30.0 million before fees and expenses. The company estimates that it will end 2007 with approximately $80M in cash and cash equivalents. Select 2008 Objectives During the briefing Sangamo will also discuss the following anticipated objectives for 2008: -- In the second half of 2008, Sangamo expects to have data from its repeat-dosing Phase 2 trial of SB-509 in patients with mild to moderate DN and anticipates completing accrual and having data from a second Phase 2 trial of the same drug in patients with moderate to severe DN. -- Dow AgroSciences has the option to exercise a commercial license for the use of our ZFP technology in plant agriculture in the second half of 2008. -- The Phase 2 trial that Sangamo plans to initiate in the first quarter of 2008 evaluating the mobilization of aldehyde bright stem cells in subjects with diabetic neuropathy after treatment with the SB-509. -- Plans for a Phase 2 trial of SB-509 for the treatment of ALS will also be outlined at the briefing. Sangamo expects to initiate this trial in the first half of 2008. -- Plans to initiate a Phase 1 trial of a ZFP Therapeutic to treat glioblastoma in the first half of 2008 and a Phase 1 trial for a ZFP Therapeutic to treat HIV infection in the second half of 2008. -- Sangamo expects to report data from the Phase 1 clinical programs in critical limb ischemia, the severe form of peripheral artery disease in 2008. -- Sangamo estimates that it expects to end 2008 with approximately $55M in cash and cash equivalents, based on current expense projections and expected progress in existing corporate relationships. The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website until December 20, 2007 and is available at via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations." About Sangamo Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ALS, cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com. This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform to specific human disease as well as plant agriculture, high value research reagents and cell-line engineering, eligibility to receive development, milestone and royalty payments from Dow AgroSciences and Sigma-Aldrich Corporation, achievement of research milestones and objectives, strategic partnerships with collaborators, clinical trials of ZFP Therapeutics and anticipated amount of cash and cash equivalents. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation, completion and outcome of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release. SOURCE Sangamo BioSciences, Inc. http://www.sangamo.com Copyright (C) 2007 PR Newswire. All rights reserved News Provided by COMTEX Close window | Back to top

2:30..Today..WASHINGTON, Jan 7 (Reuters) - U.S. regulators have delayed a final decision on whether to approve Eli Lilly and Co's (LLY.N) long-acting form of its blockbuster schizophrenia drug Zyprexa, a Food and Drug Administration spokeswoman said on Wednesday. The FDA has sent a "complete response" letter to Eli Lilly, FDA spokeswoman Sandy Walsh said. The agency issues complete response letters to companies when it is not ready to approve a drug. It does not publicly disclose what steps are needed to win approval....YET>>>>FEB..The FDA is going to get some expert help as it decides whether to finally approve prasugrel, Eli Lilly’s powerful anti-clotting drug and would-be competitor to blockbuster Plavix. Lilly and partner Daiichi Sankyo said this morning that the FDA’s Cardiovascular and Renal Drugs Advisory Committee would meet Feb. 3. The companies didn’t offer any details about what’s on the agenda, but Lilly said it has “full confidence in the data submitted to the FDA and the overall benefit-risk profile of prasugrel.” Early this year, lots of folks were brimming with anticipation for prasugrel, a more powerful clot-fighter than Plavix. But the Lilly medicine also carried a higher risk for life-threatening bleeding. Perhaps no surprise then that there was a three-month delay in FDA’s review earlier this year, then another with a less clear timetable for action, as the agency weighed what to do. It looks like the drug, whose brand-name would be Efient, will soon be on the market in Europe, since a committee there recently gave it the nod. But the FDA has shown recently, with drugs including Novartis’s Galvus and Schering-Plough’s sugammadex, that it doesn’t walk in lockstep with its European counterparts. Broken Heart by CarbonNYC via Flickr .since asco it has been down 18% but recently has had a nice uptrend breaking resistance..this is what I had for asco..UPDATE 1-Lung cancer patients live longer with Alimta -study ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) Thursday May 15, 9:00 pm ET INDIANAPOLIS, May 15 /PRNewswire-FirstCall/ -- Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved Eli Lilly and Company's ALIMTA® (pemetrexed for injection), will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., May 30 -- June 3, 2008. ADVERTISEMENT "The data presented at ASCO confirms that histology matters when treating non-small cell lung cancer," said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. "We are seeing continued affirmation that when physicians factor in a patient's histology, pemetrexed becomes an even more valuable treatment option in non-small cell lung cancer." Results from a multicenter, double-blind Phase III trial will be presented on June 2, 2008, at ASCO (Abstract # 8011). The study also was one of those featured during ASCO's live online presscast, a virtual press event that marked the first time researchers were invited to present key abstracts to the media prior to the annual meeting. The trial compared the efficacy and safety of pemetrexed versus a placebo in 663 patients with stage IIIB/IV NSCLC whose disease had not progressed after four cycles of platinum-based induction chemotherapy. According to the results, patients treated with pemetrexed demonstrated increased efficacy with respect to progression-free survival compared to those treated by placebo (4.3 months vs. 2.6 months), and pemetrexed patients also achieved better tumor response (p < 0.001). However, when data was broken down by histology, it was comparable to previous pemetrexed trials evaluating histology -- patients with a non-squamous histology fared better than those with a squamous histology. Patients with non-squamous histology who were treated with pemetrexed achieved 4.5 months of median progression-free survival compared to 2.8 months for patients with squamous histology. "The efficacy findings of this data show that pemetrexed performed better in patients with non-squamous histology for the treatment of non-small cell lung cancer," said the trial's lead investigator, Tudor Ciuleanu, M.D. of the Institutul Oncologi I Chiricuta in Cluj, Romania. Patients in the trial were treated with pemetrexed (500 mg/m2) plus best supportive care or placebo plus best supportive care. All patients were supplemented with vitamin B12, folic acid and dexamethasone. No significant toxicity differences were identified between the two trial arms with the exception of grade 3/4 anemia (pemetrexed 4.5%, placebo 1.4%) and total serious adverse events due to the treatment (pemetrexed 4.3%, placebo 0%). The data presented at ASCO reaffirmed findings from previous studies, most notably a Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic NSCLC. That study showed NSCLC patients with a non-squamous histology (those with adenocarcinoma or large cell carcinoma) demonstrated increased benefits when treated with pemetrexed(1). Lilly Drug Shown to Slow Lung Cancer By Peter Loftus Word Count: 416 | Companies Featured in This Article: Eli Lilly, ImClone Systems, Genentech, Novartis, Bristol-Myers Squibb, Merck KGaA, Roche Holding, Wyeth Eli Lilly & Co.'s Alimta delayed growth in lung cancer when used soon after initial chemotherapy, a new study concluded. Lilly's study could support broader use of Alimta, which had $854 million in sales last year. Normally, lung-cancer patients who complete first-line treatment stop therapy until new tumor growth, when they begin a second-line treatment such as Alimta. The Lilly-funded study suggests Alimta could be useful in a so-called "maintenance" phase -- a few weeks after first-line chemotherapy but before any new tumor growth ... Darn Sexy..ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included in May 15 asco Live, Online Presscast INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research. Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in asco's live online presscast. The virtual press event will be the first time asco has selected researchers to present key abstracts prior to its annual meeting. "Improved patient outcomes via tailored therapy continues to be our focus and this year's asco is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care." Key Pemetrexed Abstracts for asco 2008: -- Abstract # 8011: June 2, 2008; 3:00 p.m. -- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study -- This study will be featured during asco presscast on May 15 -- Abstract # 8096: June 1, 2008; 2:00 p.m. -- Comparison of patient outcomes stratified by histology among pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase II trials -- Abstract # 8097: June 1, 2008; 2:00 p.m. -- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin For more information on Lilly Oncology agents, including full prescribing information, please visit http://www.lillyoncology.com . (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO per OSIP cc.."This is Terry Coyne in for Geoff today. Thanks for taking the question. The question is on Alimta. We are curious to get your perspective on what you are thinking about the data for Alimta in the maintenance setting expected at ASCO, and how you ultimately think that could fit in, in lung cancer treatment? Gabe Leung Hey, Terry. This is Gabe. The only information that we know is the announcement from Lilly that they have met the primary endpoint for PFS in the Alimta maintenance study. We do not know -- we are expecting to see those data and perhaps even with survival data presented at ASCO. So, until we see it, it obviously is difficult to comment on exactly what role we think they will have. But as you well know, Alimta recently received approval for first-line treatment of adenocarcinoma in Europe, but at the same time also was restricted from being used in squamous cell cancer. So, you would argue in a way the Alimta development may well be becoming a little bit more positive for us in the second-line setting."...Also it is abstract #8011 Maintence premetrexed plus best supportive care v placebo plus BSC.A phase III study...pr...INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research. Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting. "Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care." Key Pemetrexed Abstracts for ASCO 2008: -- Abstract # 8011: June 2, 2008; 3:00 p.m. -- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study -- This study will be featured during ASCO presscast on May 15 -- Abstract # 8096: June 1, 2008; 2:00 p.m. -- Comparison of patient outcomes stratified by histology among pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase II trials -- Abstract # 8097: June 1, 2008; 2:00 p.m. -- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatinFor more information on Lilly Oncology agents, including full prescribing information, please visit www.lillyoncology.com .

2:30..This company that does big machines for labs lowered guidance on 12/12..t/a slight moving up..4% short interest...will report 1/27 normally have good qtrs..good article on the machine..http://www.boston.com/business/healthcare/articles/2009/01/05/putting_water_testing_on_the_fast_track/.....down 50% from the last JPMorgan Conf...when I wrote..Not sexy..but solid company..kissing cousin to VARI. They do Equipment for Analytical Chemist. Mass Spectom. and other equipment. 7.86B, 17.10% qt growth yoy, p/e 32.24 PEG 1.72. Does alittle better then VARI.

3..Didn't do the conf last year..they are a drug wholesaler..Value Rite, health Mart..they report on 1/26...really GREAT CHART...they get sued a lot at may settle another action on Feb 20...this is a Obama IT play and has been getting a lot of press..they normally make their qtr.

3..didn't do last conf...Needle Maker..t/a uptrending...one of Jim's favs..today settled a lawsuit. just solid defense company.

3...UP 10% since last Conf...REALLY want to go to this one...this is a Medicare Advantage Play and they have a nice chart and helping Old People with Medicare...sweet...ok here is the problem..will Obama kill it..per IBD..That's the Medicare option run by private-sector companies. Almost 25% of Medicare enrollees opt for Medicare Advantage for a total of 10.1 million Americans 65 or older. The government pays these companies for overseeing members' health care needs. Premiums vary from county to county. President-elect Obama has stated in debates that Medicare Advantage gets paid too much. A bill to cut back payments is expected to pass in some form in 2009. The average Advantage plan gets 12% more in reimbursements than government Medicare costs, wrote analyst Carl McDonald of Oppenheimer & Co. in a recent report, citing independent analyses .......so got to hear if it will...btw..they report on 2/10 and they have had some great past qtr beats and no one talks about this puppy at all...one for the radar.

3...Figures the two conferences I want to go to happen at the sametime...will probably be darling with all their newest pipeline stuff..this is the company Pfizer should really buy imho..t/a sideways.down 16% since last conf..Darn Sexy..Biotech with a lot of stuff in the pipeline and great partners. Market Cap 699.23M, SGN-40 for skin Cancer partner w/Genetech stage II. There is a great 3 part series on everything you want to know about the pipeline..this part 1, you can fine the other parts at that site. http://seekingalpha.com/article/56725-seattle-genetics-bright-future-part-i?source=yahoo.......BUT DOWN only 3% since ASSCO when I wrote.."Sexy..Should move to Phase II..8526 Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 8526) Author(s): A. Younes, A. Forero-Torres, N. L. Bartlett, J. P. Leonard, B. Rege, D. A. Kennedy, J. M. Lorenz, E. L. Sievers Abstract: Background: CD30 expression by Reed-Sternberg cells is a defining feature of Hodgkin lymphoma (HL). The ADC SGN-35 comprises an anti-CD30 antibody conjugated to monomethyl auristatin E (MMAE). SGN-35 mechanism of action involves binding to CD30 on the tumor cell surface, ADC internalization, MMAE release and binding to tubulin, prompting cell cycle arrest and apoptosis. Methods: A multicenter phase I dose escalation study was conducted in patients with refractory or recurrent CD30-positive hematologic malignancies. Twenty-nine patients (pts) were enrolled; 26 with HL, 3 with other CD30+ malignancies. Median age was 32 (range 22-87) and pts received a median of 5 prior therapies; 76% previously received an autologous stem cell transplant. Most (89%) pts had an ECOG performance status of 0/1. SGN-35 dose levels were 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.8 and 2.7 mg/kg (2-hr outpatient IV infusion, premedications not required) every 3 weeks (wks). Pts with stable disease or better after 2 doses were eligible to receive additional doses of SGN-35. Results: All pts were evaluable for safety, 28 pts were evaluable for response. Dose-limiting toxicity was not defined and 1 infusion-related reaction was observed. One pt (0.1 mg/kg) experienced G3 hypercalcemia and 1 pt (1.8 mg/kg) had G4 thrombocytopenia (both reversible and possibly related). One pt (0.4 mg/kg) experienced a possibly related myocardial infarction that resolved without sequalae. The most common related adverse events were G1/2 fatigue, diarrhea and cough. Pharmacokinetic data indicate exposure (AUC) to SGN-35 increased relative to dose level, with no accumulation after repeated dosing. Best response: partial remission (n=9), stable disease (n=11), and progressive disease (n=8). At dose levels of >1.2 mg/kg, 7 of 13 pts (54%) achieved PR and remain on therapy at 11+ to 25+ wks; tumor reductions occurred in 11 of 13 pts. Enrollment continues at 2.7 mg/kg. Conclusions: SGN-35, a novel ADC targeting CD30, was generally well tolerated at doses up to 2.7 mg/kg, and induced multiple objective responses in heavily pretreated pts. These encouraging results indicate SGN-35 should be further evaluated in phase II studies for pts with HL. Phase 1 dose SGN-35 Hodgkin lymphoma...In Jan this is what I thought of it..it is down 16% since then..Darn Sexy..Biotech with a lot of stuff in the pipeline and great partners. Market Cap 699.23M, SGN-40 for skin Cancer partner w/Genetech stage II. There is a great 3 part series on everything you want to know about the pipeline..this part 1, you can fine the other parts at that site. http://seekingalpha.com/article/56725-seattle-genetics-bright-future-part-i?source=ya...Bloomberg..Jan. 14 (Bloomberg) -- Seattle Genetics Inc., the developer of targeted drugs for cancer, had the biggest decline in more than four years in U.S. trading after the company announced plans to sell 10 million common shares. Seattle Genetics declined $1.40, or 12 percent, to $10.29 as of 4:03 p.m. New York time in Nasdaq Stock Market composite trading, the largest retreat since June 2003. The Bothell, Washington-based company will grant the underwriters, J.P. Morgan Securities Inc. and UBS Investment Bank, a 30-day option to buy an additional 1.5 million shares of common stock to cover over-allotments, according to a statement distributed by Business Wire today. J.P. Morgan and UBS are serving as joint managers of the offering. RBC Capital Markets, Needham & Company LLC and William Blair & Co. LLC are co-managers. To contact the reporter on this story: Allison Abell Schwartz in New York at aabell@bloomberg.net....blog site..While the company has a lucrative agreement to co-develop its SGN-40 therapy with Genentech, Seattle Genetics has indicated it hopes to commercialize two other therapies, SGN-35 and SGN-33, by itself. (Read an article about the company's strategy here.) The company has been especially bullish about SGN-35's prospects and plans to report more data on that treatment next month. Even with the increased spending on hiring, Seattle Genetics is not short on cash. After raising $100 million in a stock offering last year, the company estimates it will end the year with $140 million in cash and investments. Posted by Joe Tartakoff at May 6, 2008 10:43 a.m. Categories: Job cuts, Seattle Genetics, Trubion Pharmaceuticals"